Eli Lilly and Co. turned in a profitable second quarter, but the results were shy of Wall Street analyst predictions. The drugmaker, however, saw revenue growth that topped Wall Street expectations.
The Indianapolis-based company is asking U.S. regulators to revoke their emergency authorization for the use of bamlanivimab alone, in favor of its combination with another drug.
The school announced the seven-figure gift from Derica Rice and Robin Nelson-Rice on Monday. The donation will support the Kelley School’s Consortium for Graduate Study in Management.
GlaxoSmithKline and partner Vir Biotechnology Inc. have teamed up with Indianapolis-based Eli Lilly and Co. to test a combination of their COVID-19 antibody treatments to see whether they can better combat the virus and its variants together.
The U.S. Food and Drug Administration cleared the experimental drug for people 12 and older with mild or moderate symptoms not requiring hospitalization.
Lilly stock climbed Tuesday after the drugmaker laid out a better-than-expected revenue forecast and plans to buy a young company developing a potential Parkinson’s disease treatment.
The medication will be provided by the U.S. government, which paid Indianapolis-based Lilly $375 million for an initial two-month supply of 300,000 doses as part of the Operation Warp Speed program.
Eli Lilly and Co. on Thursday announced that it has agreed to acquire Disarm Therapeutics, a private biotechnology company that is developing therapies that could be used to treat multiple sclerosis, glaucoma, Alzheimer’s disease and ALS.
Lilly said it is reviewing safety data that caused federal researchers to pause a trial of the company’s COVID-19 antibody treatment in hospitalized patients. Other trials using lower doses of the drug outside the hospital will continue.
Indianapolis-based Eli Lilly and Co. said it made the decision on recommendation of the Data and Safety Monitoring Board “out of an abundance of caution.”
A long-simmering dispute between Eli Lilly and Co. and safety-net hospitals across the nation over the price of prescription drugs has reached the boiling point.
Dr. Daniel Skovronsky, chief scientific officer and president of Lilly Research Laboratories, said Lilly has already started “large-scale manufacturing” of the potential treatment.
Baricitinib, also known under the brand name Olumiant, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.
Indianapolis-based Lilly, the 12th largest employer in Indiana with 10,600 workers in the state, said it didn’t have a specific timeline for how long the precaution would last.
The pharmaceutical giant says it needs additional manufacturing capacity to keep up with demand for current medicines and new drugs expected to emerge from its pipeline.
Digging through old data to salvage a seemingly failed Alzheimer’s drug paid off big time for Biogen Inc., but at least one of its rivals has no plans to follow suit.
Indianapolis-based Lilly reported first quarter revenue of $5.09 billion, up 3% from a year ago but below analyst expectations of $5.2 billion. Sales of several of Lilly’s top drugs missed expectations.
